Artiva CMO granted 30K RSUs, 85K options

Artiva Biotherapeutics’ chief medical officer received new restricted stock units and stock options as part of equity compensation, increasing his direct holdings in ARTV.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee received equity compensation on September 9, 2026. He was granted 30,000 shares of common stock as a restricted stock unit award under the company’s 2024 Equity Incentive Plan and now directly holds 170,947 common shares.

He was also granted 85,000 stock options to purchase common stock at an exercise price of $10.79 per share, expiring on September 8, 2036. Beginning on September 8, 2026, one forty-eighth of the option shares vests in equal monthly installments over four years. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 115,000 shares

Grant/Award 2 txns

Insider Banerjee Subhashis

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F2	85,000	$0.00	$0.00
Grant/Award	Common Stock F1	30,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 85,000 contracts (Direct); Common Stock — 170,947 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
2. F2. Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

Key Figures

Restricted Stock Units Granted: 30,000 shares Stock Options Granted: 85,000 options Option Exercise Price: $10.79 per share +3 more

6 metrics

Restricted Stock Units Granted 30,000 shares Restricted stock unit award to Chief Medical Officer on September 9, 2026

Stock Options Granted 85,000 options Employee stock option grant on September 9, 2026

Option Exercise Price $10.79 per share Exercise price for 85,000 options granted to purchase common stock

Option Expiration Date September 8, 2036 Expiration of 85,000 stock options granted to the Chief Medical Officer

Post-Transaction Common Shares Held 170,947 shares Direct common stock holdings of the Chief Medical Officer after the award

Option Vesting Schedule 1/48 monthly over 4 years Vesting of option shares beginning on September 8, 2026

Key Terms

restricted stock unit award, 2024 Equity Incentive Plan, vest in equal monthly installments

3 terms

restricted stock unit award financial

"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

2024 Equity Incentive Plan financial

"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."

vest in equal monthly installments financial

"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did ARTV grant to its Chief Medical Officer on September 9, 2026?

On September 9, 2026, ARTV’s Chief Medical Officer Subhashis Banerjee received a 30,000-share restricted stock unit award and 85,000 stock options to purchase common stock at $10.79 per share as part of his equity compensation.

How many ARTV common shares does the Chief Medical Officer hold after these grants?

Following the September 9, 2026 equity awards, the Chief Medical Officer directly holds 170,947 shares of ARTV common stock, including the 30,000-share restricted stock unit award reported in this filing.

What are the key terms of the new ARTV stock options granted to the Chief Medical Officer?

The Chief Medical Officer received 85,000 stock options with an exercise price of $10.79 per share, each for ARTV common stock, expiring on September 8, 2036, with vesting in monthly installments starting in 2026.

How do the new ARTV options granted to the Chief Medical Officer vest?

Beginning on September 8, 2026, 1/48th of the 85,000 option shares vests in equal monthly installments over a four-year period, until all option shares have vested, assuming continued service under the award terms.

Were the ARTV transactions for the Chief Medical Officer made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with the Chief Medical Officer’s September 9, 2026 equity awards.

What is the nature of the 30,000-share award reported for ARTV’s Chief Medical Officer?

The 30,000-share award is a restricted stock unit award granted under Artiva Biotherapeutics’ 2024 Equity Incentive Plan, representing common stock that will be delivered based on the plan’s vesting and other conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 06:35 PM Accepted by SEC EDGAR 09/11/2026 - 06:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Banerjee Subhashis

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2026		A		30,000(1)	A	$0	170,947	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$10.79	09/09/2026		A		85,000		(2)	09/08/2036	Common Stock	85,000	$0	85,000	D

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

2. Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

	/s/ Jennifer Bush, Attorney-in-Fact	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)